During the early stages of the COVID‐19 pandemic, hospitals in London, the UK epicentre, reported an unusually high number of people presenting with COVID‐19 disease developing diabetic ketoacidosis, hyperosmolar hyperglycaemic state, or a combination of both. Very high doses of insulin were often needed to manage the hyperglycaemia. It has been proposed that these metabolic disturbances may result from severe insulin resistance combined with decreased insulin secretion due to beta cell dysfunction.


This content is not covered by the Open Government Licence. Please see source record or item for information on rights and permissions.

Cite as

Rayman, G., Lumb, A., Kennon, B., Cottrell, C., Nagi, D., Page, E., Voigt, D., Courtney, H., Atkins, H., Platts, J., Higgins, K., Dhatariya, K., Patel, M., Narendran, P., Kar, P., Newland-Jones, P., Stewart, R., Burr, O. & Thomas, S. 2020, 'Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic', Diabetic Medicine, 37(7), pp. 1214-1216. https://doi.org/10.1111/dme.14328

Downloadable citations

Download HTML citationHTML Download BIB citationBIB Download RIS citationRIS
Last updated: 27 October 2022
Was this page helpful?